Trans-Resveratrol
Friedreich Ataxia
Murdoch Childrens Research InstitutePhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
16 Active assets in the Friedreich Ataxia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Idebenone Santhera Pharmaceuticals | Phase 3 | A |
Interferon Γ-1B Amgen | Phase 3 | BB |
Omaveloxolone Biogen | Phase 3 | BB |
rt001 Biojiva LLC | Phase 3 | BB |
CITALOPRAM University of Colorado, Denver | Phase 4 | BB |
View all 38 →
Same molecule, other indications
Trans-Resveratrol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →